Tecentriq (atezolizumab) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs)	1
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.	2
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated in combination with nab-paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous, non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving TECENTRIQ.
TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering ≥ 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel